Bryant Fong - 07 Mar 2022 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: Director
Signature: /s/ Bryant Fong, by Brian Lenz as Attorney-in-fact
Issuer symbol: ADMA
Transactions as of: 07 Mar 2022
Transactions value $: $0
Form type: 4
Filing time: 09 Mar 2022, 16:58:54 UTC
Previous filing: 26 Oct 2021
Next filing: 08 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Award	$0	+26.6K	+354.48%	$0.00	34.1K	07 Mar 2022	Direct	F1, F2
holding	ADMA	Common Stock						1.43M	07 Mar 2022	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Employee Stock Option (right to buy)	Award	$0	+53.2K		$0.00	53.2K	07 Mar 2022	Common Stock	53.2K	$1.67	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
F2	Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 7,500 shares of common stock owned by the reporting person.
F3	Represents shares held by Biomark Capital Fund ("Biomark Capital"). Mr. Fong is a Managing Director and General Partner at Biomark Capital and may be deemed the beneficial owner of such shares.
F4	The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.